低分子量肝素(Low-molecular-weight heparin)是一種黏液多醣體，衍生自傅统肝素(Unfractionated heparin)，在治療深部静脈栓塞方面比傅統肝素有较多優點，例如可安全使用而毋须寶驗室之監測。我們记録一個65歲血液透析女性病人，因為深部静脈栓塞而使用低分子量肝素来冶療，而造成嚴重出血的併發症。

Low-molecular-weight heparin (LMWH), a mixture of polysaccharide molecules, is derived from unfractionated heparin (UFH) by physical and/or chemical processes. Using subcutaneous injections of LMWH to treat patients with deep vein thrombosis has several major advantages over the use of conventional intravenous or subcutaneous UFH therapy. For instance, there is no requirement for laboratory monitoring of activated partial thromboplastin time with LMWH. However, in the report we observed a 65-year-old female with end-stage renal disease and found that she, after receiving anti-coagulant treatment with Nadroparin (LMWH), developed bleeding complications. It indicates that the potential bleeding adverse effect of LMWHs should be taken into account when applied to patients with severe renal disease.